My point was not that some or even perhaps a majority of BP execs may be asleep at the switch but that not all of them would be especially wrt a paradigm changing treatment for GBM and indeed many solid tumours. Rather, I think it more likely that it is a valuation issue where NWBO and BP may be far apart. This may change if TLD is very positive. I don't believe that BP is blind to the potential of DC VAX as a mono-therapy or combination cocktail. Surely Dr. Duffy has recognised this and it is rather certain that BP realises it as well. Bottom line, I think it is a valuation issue which may be better bridged by TLD and follow-on deep dive analysis. JMHO.
Bingo. Few had the foresight to realize that micro computers, the internet, and mobile phones for that matter, would explode in popularity like they did......
News 
Market Data 
Discover 
AI
